5AM Ventures  |

5AM VenturesFounded in 2002, 5AM Ventures actively invests in next-generation life science companies. With $685 million under management, 5AM has invested in over 55 early-stage companies and its successful realizations include DVS Sciences (acquired by Fluidigm), Envoy Therapeutics (acquired by Takeda), Flexion Therapeutics, Ikaria (acquired by Mallinckrodt), Ilypsa (acquired by Amgen), Incline Therapeutics (acquired by The Medicines Company), Marcadia (acquired by Roche), Novira (acquired by J&J), Pearl Therapeutics (acquired by AstraZeneca) and Relypsa. Via its 4:59 Initiative, 5AM creates and builds therapeutics companies based on groundbreaking technologies. For more information, please visit

ARCH Venture Partners  |

ARCH Venture PartnersARCH Venture Partners invests in the development of seed and early stage advanced technology companies that have the potential to grow rapidly into successful businesses. ARCH invests primarily in companies that they co-found with leading scientists and entrepreneurs, concentrating on bringing to market disruptive innovations in life sciences, physical sciences and information technology, and specialize in the spaces where they converge. For more information, please visit

Deerfield  |

DeerfieldDeerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy. For more information, please visit

Temasek  |

Incorporated in 1974, Temasek is an investment company based in Singapore, with a S$266 billion portfolio. Temasek’s portfolio covers a broad spectrum of sectors, including financial services, telecommunications, media and technology, transportation and industrials, consumer and real estate, energy and resources and life sciences and agriculture. For more information, please visit

Open Menu